MSK
Search
- Page Path
- HOME > Search
Journal Article
- Activity of Lactobacillus crispatus isolated from vaginal microbiota against Mycobacterium tuberculosis
- Youngkyoung Lee , Hoonhee Seo , Sukyung Kim Abdur Rahim , Youjin Yoon , Jehee Jung , Saebim Lee , Chang Beom Ryu , Ho-Yeon Song
- J. Microbiol. 2021;59(11):1019-1030. Published online November 1, 2021
- DOI: https://doi.org/10.1007/s12275-021-1332-0
- 15 View
- 0 Download
- 9 Citations
-
Abstract
- Tuberculosis, an infectious disease, is caused by Mycobacterium
tuberculosis. It remains a significant public health issue
around the globe, causing about 1.8 million deaths every year.
Drug-resistant M. tuberculosis, including multi-drug-resistant
(MDR), extremely-drug-resistant (XDR), and totally drugresistant
(TDR) M. tuberculosis, continues to be a threat to
public health. In the case of antibiotic-resistant tuberculosis,
the treatment effect of conventional antibiotics is low. Side
effects caused by high doses over a long period are causing
severe problems. To overcome these problems, there is an urgent
need to develop a new anti-tuberculosis drug that is different
from the existing compound-based antibiotics. Probiotics
are defined as live microorganisms conferring health
benefits. They can be potential therapeutic agents in this context
as the effectiveness of probiotics against different infectious
diseases has been well established. Here, we report that
Lactobacillus crispatus PMC201 shows a promising effect on
tuberculosis isolated from vaginal fluids of healthy Korean
women. Lactobacillus crispatus PMC201 reduced M. tuberculosis
H37Rv under co-culture conditions in broth and reduced
M. tuberculosis H37Rv and XDR M. tuberculosis in macrophages.
Lactobacillus crispatus PMC201 was not toxic to a
guinea pig model and did not induce dysbiosis in a human
intestinal microbial ecosystem simulator. Taken together, these
results
indicate that L. crispatus PMC201 can be a promising alternative drug candidate in the current tuberculosis drug regime. Further study is warranted to assess the in vivo efficacy and confirm the mode of action of L. crispatus PMC201.
First
Prev
TOP
